We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SOURCES: FDA ENFORCEMENT NUMBERS SHOW AN AGENCY STRETCHED TOO THIN

SOURCES: FDA ENFORCEMENT NUMBERS SHOW AN AGENCY STRETCHED TOO THIN

June 26, 2006

The FDA's own enforcement reports show it to be an agency under increasing pressure to do more with less -- the number of warning letters is dropping even as recalls skyrocket, sources say.

The FDA required 5,338 recalls last year, according to enforcement numbers obtained by FDAnews. The recalls represent an 11-year high and represent a significant increase from the 4,670 issued in 2004, FDA documents show. The recall numbers are available at: http://www.fda.gov/ora/about/enf_story/ch10/Recalls.pdf (http://www.fda.gov/ora/about/enf_story/ch10/Recalls.pdf).

Meanwhile, the number of Form 483 warning letters is continuing to drop, with the agency issuing 535 in 2005 as compared with 725 the previous year. The warning letter data is available at: http://www.fda.gov/ora/about/enf_story/ch10/10yrWL.pdf (http://www.fda.gov/ora/about/enf_story/ch10/10yrWL.pdf).

These numbers illustrate an agency that is allowing more mistakes to reach the market, requiring an ever greater number of recalls, Gordon Richman, vice president of strategic compliance and general counsel of the consulting firm EduQuest, told FDAnews. The numbers also are a sign of rising quality system or manufacturing errors in industry, which allow flawed products to get into the market, he said.

This data "doesn't paint a very encouraging picture" as to where the agency's enforcement efforts are headed, Richman added. But both he and a consumer activist who assessed these numbers stressed that the FDA was not to blame -- Congress is.

"This is not the agency's fault, it is Congress' fault in not adequately funding the agency," the consumer advocate, who asked not to be named, added. Specifically, Congress and the president's budgets are not keeping up with the rate of inflation and the increased responsibilities the FDA must address, Richman and the source said. The agency needs more investigators and an updated information technology system, including databases, that helps to better track problems in medical product development, the consumer advocate added. (http://www.fdanews.com/did/5_124/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing